What molecule am I?
Phosphinine (aka phosphorine, phosphorin, and phosphabenzene1) is a heteroaromatic compound that is the phosphorus analogue of pyridine. It was first described in 1961 by H. Depoorter, J. Nys, and A. Van Dormael at Gevaert Photo-Producten N.V. (Mortsel, Belgium) in an article on , although none of the dyes contained the phosphinine structure.
In 1968, Karl Dimroth and co-workers at Philipps University of Marburg (Germany) wrote about the , but the work pertained only to phosphinine derivatives. But 3 years later, Arthur A. Ashe III at the University of Michigan (Ann Arbor) reported the and the related heteroarene arsabenzene2. Ashe and Paul Shu treated the previously prepared molecule 3 with phosphorus tribromide4 to form the hydrobromide salt of phosphinine, then added base to give the unsubstituted compound. They found that phosphinine/phosphabenzene is an air-sensitive but otherwise stable colorless, volatile liquid. Arsabenzene was similarly prepared by using arsenic trichloride5 in place of phosphorus tribromide. In 2016, Ashe wrote an about the background of his syntheses of phosphabenzene and its analogues.
Although phosphinine derivatives have been studied since the 1970s, few reports involve the base compound. In one from 2020, Jan 艠ez谩膷 聽at the Czech Academy of Science (Prague) included phosphinine (as phosphorine) in a dataset of the of . And in 2024, Slavko Radenkovi膰 at the University of Kragujevac (Serbia), Miquel Sol脿 at the University of Girona (Spain), Henrik Ottosson at Uppsala University (Sweden), and co-workers included the molecule in their study of the lowest excited n,蟺* states of heteroaromatic compounds. Among other findings, they concluded that the .
Phosphinine is not an article of commerce; thus, no hazard information is available.
1. These terms are used interchangeably in this article.
2. CAS Reg. No. 289-31-6.
3. CAS Reg. No. 31732-31-7.
4. CAS Reg. No. 7789-60-8.
5. CAS Reg. No. 7784-34-1.
Lorundrostat1 is a hypertension medication being developed by Mineralys Therapeutics (Radnor, PA). It was first described in 2015 by Ushirogochi Hideki and co-inventors at Mitsubishi Tanabe Pharma (Osaka, Japan) in world patent WO2015163427.
Lorundrostat is targeted at patients with uncontrolled hypertension caused by aldosterone dysregulation. In April, Steven E. Nissen at Cleveland Clinic and collaborators at Mineralys and several other US institutions reported the results of a 285-patient study of the medication, an aldosterone synthase inhibitor. The results showed that patients who received the drug had compared with the placebo group members.
1. CAS Reg. No. 1820940-17-7.
Molecule of the Future
Once a month we bring you a newly discovered or developed molecule that has important implications for the future of chemistry or society in general. Look for it the third week of each month.聽Learn more about this month's Molecule of the Future.
We're looking for more molecules of the future!
Do you have a suggestion for the next molecule of the future? Send your idea to MOTW.
This molecule was suggested by a reader. We present聽almost all of the molecules suggested by our readers.聽If you have a molecule you would like us to consider, please send us a message. And thank you for your interest in Molecule of the Week! 鈥擡d.
笔丑辞蝉辫丑颈苍颈苍别听
fast facts
| CAS Reg. No. | 289-68-9 |
| 厂肠颈贵颈苍诲别谤听苍补尘别 | Phosphorin |
| Empirical formula | C5H5P |
| Molar mass | 96.07 g/mol |
| Appearance | Colorless liquid |
| Boiling point | 93鈥�94 潞C |
| Water solubility | Not reported; probably slight |
, the most authoritative and comprehensive source for chemical information.
Molecule of the Week needs your suggestions!
If your favorite molecule is not in our聽archive, please send us a message. The molecule can be notable for its current or historical importance or for any quirky reason. Thank you!
Stay Ahead of the Chemistry Curve
Learn how ACS can help you stay ahead in the world of chemistry.
